Top Page
Healios KK
(4593)
Healios KK (4593) vs. iShares MSCI Japan ETF (EWJ)
Healios KK Business Overview & Revenue Model
Healios KK Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 104.00M | 560.00M | 121.00M | 90.00M | 41.00M |
| Gross Profit | -389.00M | 432.00M | 108.00M | 90.00M | 41.00M |
| EBITDA | -3.13B | -2.54B | -3.16B | -4.52B | -3.61B |
| Net Income | -2.22B | -4.24B | -3.82B | -5.17B | -4.91B |
Balance Sheet | |||||
| Total Assets | 17.05B | 14.19B | 15.15B | 15.03B | 23.97B |
| Cash, Cash Equivalents and Short-Term Investments | 5.68B | 3.67B | 6.72B | 7.25B | 15.13B |
| Total Debt | 3.04B | 2.66B | 4.53B | 7.15B | 11.96B |
| Total Liabilities | 12.15B | 12.11B | 11.29B | 10.65B | 15.33B |
| Stockholders Equity | 4.89B | 2.06B | 3.86B | 4.38B | 8.64B |
Cash Flow | |||||
| Free Cash Flow | -3.33B | -1.83B | -2.85B | -4.86B | -5.39B |
| Operating Cash Flow | -3.17B | -1.82B | -2.82B | -4.60B | -5.09B |
| Investing Cash Flow | -1.11B | -1.42B | -1.12B | -909.00M | -736.00M |
| Financing Cash Flow | 6.33B | 77.00M | 3.34B | -2.50B | 6.99B |
Healios KK Technical Analysis
Healios KK Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | ¥17.82B | -54.84 | ― | ― | 1.24% | -33.41% | |
54 Neutral | ¥32.33B | -70.05 | ― | ― | -5.65% | -469.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥59.40B | -18.92 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥14.17B | -11.63 | ― | ― | -42.49% | -2.37% | |
48 Neutral | ¥176.20B | -46.79 | -636.97% | ― | ― | -12.69% | |
43 Neutral | ¥19.24B | -10.06 | ― | ― | ― | 11.34% |
Healios KK Corporate Events
Healios K.K. plans to reduce portions of its capital stock and capital reserves and transfer these amounts to other capital surplus, before reallocating surplus to retained earnings to eliminate carry-forward losses and lower its tax burden. The transaction, scheduled to take effect in late April 2026 pending shareholder approval and creditor procedures, will not alter the number of outstanding shares, shareholder holdings or net asset value per share, indicating a balance sheet reclassification rather than a change in the company’s overall financial strength.
By resetting retained earnings to zero through this internal reallocation, Healios aims to clean up its capital structure and improve future flexibility for potential dividends or capital policy measures once profitability is achieved. The move may enhance the company’s financial transparency and tax efficiency without immediate economic dilution for shareholders, while signaling management’s intent to address accumulated losses within the constraints of Japanese company law.
The most recent analyst rating on (JP:4593) stock is a Hold with a Yen367.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. has nominated five candidates for its Board of Directors, including Chairman Hardy TS Kagimoto as director, current CFO Richard Kincaid as director, and three outside directors, Seigo Kashii, Yuko Yogo, and Glenn Gormley. The nominations, decided by the Board following the Nomination Committee’s recommendations, will be submitted for approval at the company’s 15th Ordinary General Meeting of Shareholders on March 25, 2026.
The company has also proposed Kouichi Tamura as an alternate director to ensure the board maintains the legally required number of members if vacancies arise. The refreshed board slate, with a mix of internal leadership and multiple outside directors, underscores Healios’ focus on independent oversight and governance stability as it advances its regenerative medicine initiatives and navigates its growth phase on the TSE Growth Market.
The most recent analyst rating on (JP:4593) stock is a Hold with a Yen367.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. released its FY2025 financial results materials primarily to disclose information to investors and other stakeholders, emphasizing that the data and analysis are provided for informational purposes only. The company underscores that the materials are not an offer or solicitation to buy or sell securities, and that the contents may change without notice as economic, regulatory and market conditions evolve.
The announcement highlights extensive caution around forward-looking statements, noting that projections and plans are based on current assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially. Healios also stresses that it does not guarantee the accuracy or completeness of the information, is under no obligation to update it, and that third-party data has not been independently verified, while information about regenerative medicine products is not intended as advertising or medical advice.
The most recent analyst rating on (JP:4593) stock is a Hold with a Yen358.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. has begun preparations to initiate patient enrollment in Japan for the global Phase 3 REVIVE-ARDS trial of its stem cell therapy HLCM051 (invimestrocel) in pneumonia-induced acute respiratory distress syndrome (ARDS), following completion of regulatory review by the Pharmaceuticals and Medical Devices Agency. The pivotal, placebo-controlled, double-blind study, which will enroll up to 550 patients across the U.S., Japan, Asia-Pacific and Europe, uses ventilator-free days as the primary endpoint and includes interim analyses that may allow early termination if efficacy is confirmed, underscoring the potential for Healios to advance a first-in-class therapy in a high-mortality condition with no approved drugs that directly improve prognosis, although the company does not expect a near-term impact on its 2026 financial results.
The most recent analyst rating on (JP:4593) stock is a Hold with a Yen358.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. has signed a letter of intent with Japanese pharmaceutical wholesaler Alfresa Corporation to establish a framework for the continuous sale and purchase of its human bone marrow-derived somatic stem cell culture supernatant, HLSI071. Building on an existing business alliance covering distribution and sales, the agreement is intended to secure stable, efficient nationwide distribution of the culture supernatant via Alfresa’s extensive network, enhancing timely delivery to customers. With the launch of its own manufacturing facility for culture supernatant, Healios will end earlier discussions on a potential manufacturing alliance with Alfresa group company Cell Resources, signaling a shift to in-house production while leveraging Alfresa for market access. The company stated that the arrangement is not expected to affect its consolidated financial results for the current fiscal year, but it strengthens its commercialization infrastructure in Japan’s regenerative medicine market.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen301.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. has submitted a clinical trial plan notification to Japan’s Pharmaceuticals and Medical Devices Agency to begin domestic participation in the pivotal global Phase 3 REVIVE-ARDS study of its stem cell therapy HLCM051 (invimestrocel) for pneumonia-induced acute respiratory distress syndrome, with Japanese patient enrollment expected to start following a 14-day review period before expanding in parallel to other regions including the US, Asia-Pacific and Europe. The trial, designed as a randomized, placebo-controlled study of up to 550 patients with interim analyses and ventilator-free days as the primary endpoint, will serve as a key confirmatory study supporting the company’s strategy to seek conditional and time-limited approval for ARDS in Japan based on positive Phase 2 results, marking a significant step in advancing a potential first-in-class therapy in an area with no approved drugs that directly improve prognosis, though the company expects no immediate impact on its 2026 financial guidance.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen301.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. disclosed that a lawsuit has been filed against the company by AND medical group in the Tokyo District Court, alleging default and incomplete performance under a joint research agreement signed in April 2024 concerning the use of Healios technology and culture supernatant. AND medical group is seeking ¥120 million in damages plus litigation costs, but Healios maintains that it has properly fulfilled its contractual obligations, considers the claims entirely without merit, and intends to defend its position in court while continuing discussions with multiple partners for culture supernatant sales, stating that its current business policy remains unchanged.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen286.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. has announced changes in its management and organizational structure, effective January 1, 2026. Notably, Yoshie Tsurumaki will become an Executive Officer, leveraging her extensive experience in cell therapy and oncology to lead the newly established Medical Affairs Division. This strategic move is expected to enhance the company’s engagement with healthcare professionals and improve the medical value of its products, potentially strengthening its position in the regenerative medicine market.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen401.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios KK announced its development policy for HLCM051, prioritizing its use as a treatment for ARDS. The company plans to initiate a global Phase 3 study in early 2026, with patient enrollment starting in Japan and expanding to the United States. While discussions continue for the ischemic stroke treatment under the SAKIGAKE Designation System, the application will not proceed in a rolling submission format by early 2026. This development strategy is not expected to impact the company’s financial results for the fiscal year ending December 2025.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen401.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.